Survival for patients with mantle cell lymphoma has improved dramatically over the last 2 decades owing to a better understanding of disease biology and the development of more effective treatment regimens for patients with untreated and relapsed disease. With these advancements, we are now poised to ask questions that challenge old treatment strategies, use new technologies, and improve our understanding of disease heterogeneity. This article focuses on questions that we believe will drive the future of mantle cell lymphoma treatment. Although not an exhaustive list, we review current literature, ongoing studies, and provide expert opinion on future trial design.
Keywords: Chimeric antigen receptor T-cell (CAR-T); Mantle cell lymphoma; Mantle cell lymphoma international prognostic index (MIPI); Minimal residual disease (MRD); Novel agents; Precision therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.